Navigation Links
Vion Pharmaceuticals to Present Data on Onrigin(TM)at the ASCO(R) Annual Meeting
Date:5/29/2009

NEW HAVEN, Conn., May 29 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) today announced that an analysis of clinical data of its lead anticancer agent Onrigin (laromustine) Injection in acute myeloid leukemia (AML) would be presented in a poster at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Florida.

The poster (Abstract #7050) entitled "Comorbidity Description Using the Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) in Elderly de novo Poor Risk AML Patients Treated with Laromustine" will be presented at the Orange County Convention Center, Level 2, West Hall C, Board #M4 from 8:00 a.m. to 12:00 p.m. on Saturday, May 30, 2009. A copy of the poster will be available on Vion Pharmaceuticals' website, www.vionpharm.com, on May 30, 2009 at 8:00 a.m. Eastern Time.

In addition, the Company announced that additional data on Onrigin would be presented in a poster from an investigator-sponsored trial of Onrigin in combination with cytarabine in elderly patients with previously untreated AML. The trial is sponsored by the Weill-Cornell Medical College. The poster (Abstract #7054) entitled "Phase I Trial of Laromustine in Combination with Infusional Ara-C in Elderly Patients Over Age 60 with Newly Diagnosed AML or High-Grade MDS" will be presented at the Orange County Convention Center, Level 2, West Hall C, Board #M10 from 8:00 a.m. to 12:00 p.m. on Saturday, May 30, 2009.

About Vion

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative oncology therapeutics. Vion has two agents in clinical trials, Onrigin (laromustine) Injection and Triapine(R). The Company has an NDA under review with the FDA fo
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Amylin Pharmaceuticals to Present Compelling Efficacy and Safety Data From Diabetes Programs at ADA 2009
2. American Academy of Dermatology Recognizes Merz Pharmaceuticals
3. Transcept Pharmaceuticals to Present at Needham Life Sciences Conference on June 10, 2009
4. Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program
5. Poniard Pharmaceuticals Announces Positive Efficacy and Safety Data From Phase 2 Clinical Trial of Picoplatin in Men With Metastatic Prostate Cancer
6. Verus Pharmaceuticals Announces a Lawsuit Against AstraZeneca AB and Tika Lakemedel AB
7. Access Pharmaceuticals Provides Update on Global Launch of MuGard(TM)
8. MAP Pharmaceuticals Phase 3 Trial of LEVADEX(TM) Migraine Product Candidate Meets All Four Primary Endpoints
9. Agios Pharmaceuticals founders author Science review on cancer metabolism
10. Transcept Pharmaceuticals Presents Data from Studies of Two Product Candidates at Annual Meeting of the American Psychiatric Association
11. Celator(R) Pharmaceuticals Initiates Research Agreement With Cephalon, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... (PRWEB) July 29, 2014 A leading ... Social Security disability trust fund by reallocating payroll taxes ... new poll by The Senior Citizens League (TSCL) ... said shifting revenues from the Social Security retirement trust ... to fix the disability program’s financing. “TSCL believes this ...
(Date:7/28/2014)... 2014 The “Tissue Diagnostics ... Digital pathology & Workflow, Special Staining), Disease ... Non Small Cell Lung Cancer and Others), ... companies, Research Laboratories, Contract Research Organizations and ... BRIC, Japan & RoW) - Trends & ...
(Date:7/28/2014)... July 28, 2014 A January ... of gluten intake in those who were self-diagnosed gluten-intolerant ... director of nutrition for San Diego health and wellness ... gluten considerations for those who are unclear about the ... that gluten is a protein, found in wheat, barley, ...
(Date:7/28/2014)... Dotinga HealthDay Reporter MONDAY, ... humans just milliseconds to look at someone,s face and judge ... finds that certain facial features seem to trigger specific first ... size of the mouth, for example, appear directly linked to ... attractiveness. The study findings suggest that first impressions ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Shofner ... Operation Military June . Renowned LASIK and Cataract ... to provide significant funds and public awareness for ... retired military personnel and their families. “This was ... proudly give nearly $5,000 to a variety of ...
Breaking Medicine News(10 mins):Health News:The Senior Citizens League Finds No Support Among Seniors for Likely Disability Trust Fund Fix 2Health News:The Senior Citizens League Finds No Support Among Seniors for Likely Disability Trust Fund Fix 3Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 2Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 3Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 4Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 5Health News:VeraVia Explains the Basics of Gluten-Intolerance Following Industry Study 2Health News:VeraVia Explains the Basics of Gluten-Intolerance Following Industry Study 3Health News:Facial Dimensions May Be Key to First Impressions 2Health News:Facial Dimensions May Be Key to First Impressions 3Health News:Shofner Vision Center’s “Operation Military June” Provided Funds For Local Not-For-Profit Organizations Supporting Military And Their Families 2Health News:Shofner Vision Center’s “Operation Military June” Provided Funds For Local Not-For-Profit Organizations Supporting Military And Their Families 3
... Importance of Allergy Testing to Control Chronic ... ... Allergy and asthma specialists,from around the country will gather this week ... for,the Diagnosis and Management of Asthma. These guidelines are intended to,improve ...
... Studies have shown that surgery combined with Intraperitoneal Hyperthermic ... with peritoneal carcinoma (cancer of the lining of the ... cancer. , Researchers from Wake Forest University School of ... use of IPHC in treating peritoneal cancer that has ...
... WASHINGTON, March 14 Last night, the U.S.,Senate ... for,Legislative and Public Affairs for the U.S. Agency ... Bureau for Legislative and Public Affairs, Grieco will,manage ... public,and constituent groups to communicate the agency,s mission, ...
... scientists suggests a safer way to treat medulloblastoma, a ... found that one of the brains signaling pathways inhibits ... , The researchers discovered that three proteins, designated BMP2, ... and induced the malignant cells to develop into normal ...
... moved from colon, appendix , , FRIDAY, March 14 (HealthDay ... spread to the peritoneum -- the membrane lining the ... of chemotherapy can improve survival rates, Wake Forest University ... two Wake Forest studies presented at this week,s annual ...
... team of researchers in Bedford, Mass. has developed a ... detect signs of Alzheimer,s disease. , In the ... by the Optical Society of America, the team describes ... taken from different autopsies and correctly identified which samples ...
Cached Medicine News:Health News:NIH Asthma Guidelines Will Leave Sufferers Breathing Easier This Spring 2Health News:Researchers study new drug and indications for heated chemotherapy treatment 2Health News:Jeffrey J. Grieco Confirmed as USAID Assistant Administrator for Legislative and Public Affairs 2Health News:St. Jude finds signaling system that halts the growth of a childhood brain cancer 2Health News:St. Jude finds signaling system that halts the growth of a childhood brain cancer 3Health News:Combo Treatment Ups Survival When Cancer Spreads to Abdominal Lining 2Health News:Researchers use light to detect Alzheimer's 2Health News:Researchers use light to detect Alzheimer's 3
(Date:7/28/2014)... HOUSTON , July 28, 2014  Houston ... announces that he offers orthodontic treatment with Invisalign. ... area patients can have their teeth straightened without ... same long-term benefits associated with other types of ... enjoy natural looks in addition to better support ...
(Date:7/28/2014)... Fla. , July 28, 2014  TNI ... a biopharmaceutical company focused on the development, marketing ... it has filed definitive proxy materials with the ... 2014 Annual Meeting of Shareholders to be held ... East Standard Time. The record date for determining ...
(Date:7/28/2014)... -- ResMed (NYSE: RMD ), innovatore e ... disturbi respiratori del sonno (SDB) e altre patologie croniche ... contro il produttore Taiwanese di dispositivi medicali, APEX Medical ... indossare in testa, che violano i brevetti, utilizzate con ... della Corte Regionale Distrettuale di Monaco ...
Breaking Medicine Technology:Houston Cosmetic Dentist, Dr. Behzad Nazari, Now Offers Orthodontic Treatment with Invisalign 2TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 2TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 3ResMed riceve un'ingiunzione permanente contro APEX in Germania, continua a far valere i propri diritti per i brevetti in Europa 2
... Md., May 24, 2007 /PRNewswire-FirstCall/ -- Iomai,Corporation today ... 1 trial of its patch-based needle-free influenza vaccine,before ... live,webcast will be held at 8:30 a.m. Eastern ... Details , To access the live conference call ...
... Texas--(BUSINESS WIRE)--May 29, 2007 - Introgen,Therapeutics, Inc. ... updated Phase 2 clinical trial results,for its ... upcoming,annual meetings of The American Society of ... Society of Gene Therapy (ASGT) in,Seattle., "We ...
Cached Medicine Technology:Iomai to Announce Results From Phase 1 Influenza Trial and Host,Webcast Tomorrow 2Introgen and Clinical Collaborators to Report New Results with,Advanced-Stage Cancer Therapies at Upcoming Medical Meetings 2Introgen and Clinical Collaborators to Report New Results with,Advanced-Stage Cancer Therapies at Upcoming Medical Meetings 3
The REVEALRT and REVEALXVI PET/CT scanners combine our fastest PET scanner, the REVEALXL, with multi-slice spiral CT scanners from Siemens Medical Systems....
... a second generation device, having evolved from ... over 700 patients beginning in 1989. Designed ... cardiologists who perform these procedures, CardioSEAL has ... the engineering bench, and in animals. In ...
Allows surgeons to successfully complete coronary artery bypass without cross clamping or side biting. Saphaneous vein grafts may be attached to the aorta without sutures....
... treat a diverse range of patients suffering ... retinal disease. Compact, Space Saving Design - ... health care professionals to use the system ... Water-cooled: The power consumption is saved by ...
Medicine Products: